Moderna Says Its COVID-19 Vaccine Is, Safe and Effective, in 12- to 17-Year-Olds.
On Tuesday, Moderna announced the results of their
Phase 2 trial of the administration of their COVID-19
vaccine to children ages 12 to 17. .
According to results involving 3,732 children
in the United States, their vaccine produces an
immune response to COVID-19.
That immune response was found to be equivalent
to the immune response produced in adults. .
Moderna’s results in the children were “consistent
with a vaccine efficacy of 100%.”.
The vaccine was found to be 93 percent effective at
preventing mild cases of COVID-19 after one dose. .
These mild cases only involved one symptom
of COVID-19, rather than two or more. .
No significant safety concerns were identified:
only mild side effects after the second dose such as headache,
fatigue, muscle pain, pain at the injection site and chills.

Moderna plans to submit their findings
and a request for authorization to the U.S. Food
and Drug Administration in early June. .
Currently, Pfizer’s COVID-19 vaccine is the only
one to have gained emergency use authorization
from the FDA to include 12- to 15-year-olds